Healthcare / BiotechnologyShanghai
$44.96
+1.35 (+3.10%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-19.6M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
47/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.3B
P/E
145.0x
↑EV/EBITDA
42.3x
↑ROE
2.0%
↑Gross Margin
50.8%
↑Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+6.4%
FCF CAGR
—
FCF margin
13.3%
FCF / Net income
1.13x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $354.9M · net income $41.7M · FCF $47.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $354.9M | $354.9M | $297.2M | $243.1M | $294.4M |
| Net Income | $41.7M | $41.7M | $21.1M | $54.0M | $105.4M |
| EBITDA | $102.5M | $102.5M | $85.6M | $101.7M | $158.3M |
| EPS | 0.37 | 0.37 | 0.18 | 0.47 | 1.04 |
| Gross Margin | 50.8% | 50.8% | 53.0% | 58.8% | 64.0% |
| Operating Margin | 10.7% | 10.7% | 6.0% | 13.7% | 35.3% |
| Net Margin | 11.7% | 11.7% | 7.1% | 22.2% | 35.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | 0.03 | 0.03 | 0.04 |
| Current Ratio | 1.90 | 1.90 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $47.3M | $47.3M | $-51.6M | $-19.6M | $-35.3M |
| Returns | |||||
| ROE | 2.0% | 2.0% | 1.0% | 2.5% | 4.8% |
| Valuation | |||||
| P/E | 145.03 | 145.03 | 203.22 | 110.21 | 78.85 |
| EV/EBITDA | 42.32 | 42.32 | 40.35 | 46.62 | 43.56 |
| P/B | 2.41 | 2.41 | 2.04 | 2.76 | 3.80 |
| Growth & Yield | |||||
| Revenue Growth | 19.4% | 19.4% | 22.3% | -17.4% | — |
| EPS Growth | 105.6% | 105.6% | -61.7% | -54.8% | — |
| Dividend Yield | 1.0% | 1.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
120.9%
EPS terminal req.
$3.99
Spread vs growth
-15.4%
5Y implied EPS CAGR
67.1%
EPS terminal req.
$4.83
Spread vs growth
38.4%
10Y implied EPS CAGR
35.6%
EPS terminal req.
$7.77
Spread vs growth
70.0%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+6.3%
Start / end P/E
237.3x → 121.5x
EPS bridge
0.18 → 0.37
Residual
-51.5%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.